LX7101 Hydrochloride/LX7101

Solubility:DMSO

Biologieal

The target of LX7101 is a kinase that is responsible for regulating intraocular pressure.  IOP levels can become elevated due to increased resistance in the fluid outflow facility in the eye.  LX7101 is intended to lower IOP by enhancing the fluid outflow facility of the eye.  The goal of the LX7101 program is to develop a once-daily eye drop that lowers IOP by increasing the fluid outflow facility in the eye, a novel mechanism not currently addressed by approved products for glaucoma

Reference

http://www.lexpharma.com/pipeline/lx7101.html